KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $0.1.

  • AbbVie's EPS (Basic) fell 8863.64% to $0.1 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.32, marking a year-over-year decrease of 5416.67%. This contributed to the annual value of $2.42 for FY2024, which is 1125.14% down from last year.
  • As of Q3 2025, AbbVie's EPS (Basic) stood at $0.1, which was down 8863.64% from $0.53 recorded in Q2 2025.
  • AbbVie's EPS (Basic)'s 5-year high stood at $2.52 during Q1 2022, with a 5-year trough of -$0.01 in Q4 2024.
  • Moreover, its 5-year median value for EPS (Basic) was $0.77 (2024), whereas its average is $1.03.
  • As far as peak fluctuations go, AbbVie's EPS (Basic) soared by 2230948.82% in 2021, and later crashed by 10278.97% in 2024.
  • Quarter analysis of 5 years shows AbbVie's EPS (Basic) stood at $2.29 in 2021, then plummeted by 38.92% to $1.4 in 2022, then plummeted by 66.61% to $0.47 in 2023, then plummeted by 102.79% to -$0.01 in 2024, then soared by 869.13% to $0.1 in 2025.
  • Its EPS (Basic) was $0.1 in Q3 2025, compared to $0.53 in Q2 2025 and $0.72 in Q1 2025.